The National Health Surveillance Agency (Anvisa) reported that, on Monday, 28, a meeting was held with technicians from the agency and the Butantan Institute to discuss the Butanvac vaccine against covid-19. According to the agency, the clinical research protocol is already approved, but there is still a lack of specific data to start the tests in humans.
In a note, the regulatory body states that the purpose of the meeting was to evaluate the information already presented by Butantan. “But for the vaccine to start being applied to human beings, it is necessary to present specific data, which are still being generated by Butantan”, he says. According to Anvisa, an example of the missing data refers to the inactivation of the virus used in the vaccine.
Read Also
- Oxford Recovery Trial – A pharmacokinetic model wrong leading to the overdose Jul 3, 2020
- Coronavirus According to Hus’s assistant chief physician, the delta transformation may be the prelude to even more danger Jul 26, 2021
- Debunked popular myths about the benefits of walnuts Jul 14, 2020
- China has successfully tested a vaccine against coronavirus Jun 28, 2020
- Coronavirus : Catalonia in the face of the upsurge of the infections Jul 13, 2020
- Named the best product to protect from hypertension Jul 12, 2020
- Military exercise of unprecedented scale in France in 2023 Nov 16, 2022